Related Experiment Video
Updated: Jun 27, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Human astrovirus coat protein: a novel C1 inhibitor
Neel K Krishna1, Kenji M Cunnion
1Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23507, USA. krishnnk@evms.edu
Insights
Researchers discovered a novel inhibitor of C1, the astrovirus coat protein. This protein blocks complement activation, offering potential therapeutic benefits for inflammatory diseases.
Area of Science:
- Immunology
- Virology
- Biochemistry
Background:
- The complement system's classical pathway, initiated by the C1 complex (C1q, C1r, C1s), plays a crucial role in pathogen defense and immune regulation.
- Dysregulated complement activation is implicated in various autoimmune and inflammatory conditions, necessitating effective control mechanisms.
- Existing inhibitors of C1 are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To identify and characterize novel inhibitors of the C1 complex.
- To investigate the potential of viral proteins as modulators of complement activation.
- To explore the therapeutic implications of inhibiting the classical complement pathway.
Main Methods:
- Identification of astrovirus coat protein as a C1 inhibitor.
- Biochemical analysis of the interaction between astrovirus coat protein and C1q.
- Assessment of the inhibitory effects on C1 complex activation and classical pathway function.
Main Results:
- The astrovirus coat protein binds to the A-chain of C1q, effectively inhibiting C1 complex activation.
- This inhibition suppresses both spontaneous and antibody-mediated classical pathway activation.
- The study reports the first instance of a non-enveloped virus inhibiting complement and a viral inhibitor of C1.
Conclusions:
- The astrovirus coat protein represents a novel class of C1 inhibitors.
- This viral protein demonstrates significant potential as an anti-complement therapeutic agent.
- Targeting C1 activation offers a promising strategy for managing complement-mediated inflammatory diseases.
Abstract:
C1 is a multimolecular complex that initiates the classical pathway of complement. It is composed of the pattern recognition component C1q and the serine proteases C1r and C1s. Activation of C1 elicits a series of potent effector mechanisms directed at limiting infection by invading pathogens as well as participating in other biological functions such as immune tolerance. While many molecules in addition to antibody have been demonstrated to activate C1, only a handful of C1 inhibitors have been described. Disregulated control of complement activation is associated with numerous autoimmune and inflammatory disease processes, thus tight regulation of C1 activation is highly desirable. We have recently discovered a novel inhibitor of C1, the coat protein of the human astroviruses, a family of enteric pathogens that infect young children. The astrovirus coat protein binds to the A-chain of C1q and inhibits spontaneous as well as antibody-mediated activation of the C1 complex resulting in suppression of classical pathway activation and complement-mediated terminal effector functions. This is the first description of a non-enveloped icosahedral virus inhibiting complement activation and the first description of a viral inhibitor of C1. The known inhibitors of C1 are reviewed and then discussed in the context of this novel viral C1 inhibitor. Additionally, the properties of this compound are elucidated highlighting its potential as an anti-complement therapeutic for the many diseases associated with inappropriate complement activation.
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Cytomegalovirus Disease
Arboviral Encephalitis

